7th Nov 2006 16:00
7 November 2006Interim IFRS Report for the six month ended 30 June 2006Copies of the above document have been submitted to the UK Listing Authorityand will shortly be available for inspection at the UK Listing Authority'sDocument Viewing Facility, which is situated at:Document Viewing FacilityUK Listing AuthorityFinancial Services Authority25 the North ColonnadeCanary WharfLondon E14 5HSTel (0)20 7676 1000T MayCompany SecretaryFor further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on attention deficit and hyperactivity disorder (ADHD),human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. Thestructure is sufficiently flexible to allow Shire to target new therapeuticareas to the extent opportunities arise through acquisitions. Shire believesthat a carefully selected portfolio of products with a strategically alignedand relatively small-scale sales force will deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com.Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 5492592Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire